M
Manfred Hensel
Researcher at Heidelberg University
Publications - 75
Citations - 5380
Manfred Hensel is an academic researcher from Heidelberg University. The author has contributed to research in topics: Rituximab & Chronic lymphocytic leukemia. The author has an hindex of 30, co-authored 73 publications receiving 5070 citations. Previous affiliations of Manfred Hensel include German Cancer Research Center & Praxis.
Papers
More filters
Journal ArticleDOI
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek,Kirsten Fischer,Günter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiří Mayer,Manfred Hensel,Georg Hopfinger,G D Hess,U. Von Grünhagen,Matthias Bergmann,John Catalano,Pier Luigi Zinzani,Federico Caligaris-Cappio,John F. Seymour,Alain Berrebi,Ulrich Jäger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens M. Wendtner,Barbara Eichhorst,Peter Staib,Andreas Bühler,Dirk Winkler,Thorsten Zenz,S Böttcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Döhner,Stephan Stilgenbauer +31 more
TL;DR: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes.
Journal ArticleDOI
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Barbara Eichhorst,Raymonde Busch,Georg Hopfinger,Rita Pasold,Manfred Hensel,Cordelia Steinbrecher,Siegfried Siehl,Ulrich Jäger,Manuela Bergmann,Stephan Stilgenbauer,Carmen D. Schweighofer,Clemens M. Wendtner,Hartmut Döhner,Günter Brittinger,Bertold Emmerich,Michael Hallek +15 more
TL;DR: First-line treatment with FC increases the response rates and the treatment-free interval in younger patients with advanced CLL and no difference in median overall survival has been observed.
Journal ArticleDOI
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz,Barbara Eichhorst,Raymonde Busch,Tina Denzel,Sonja Häbe,Dirk Winkler,Andreas Bühler,Jennifer Edelmann,Manuela Bergmann,Georg Hopfinger,Manfred Hensel,Michael Hallek,Hartmut Döhner,Stephan Stilgenbauer +13 more
TL;DR: CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy, and patients with TP 53 mutation should be considered for alternative treatment approaches.
Journal ArticleDOI
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer,Thorsten Zenz,Dirk Winkler,Andreas Bühler,Richard F. Schlenk,Silja Groner,Raymonde Busch,Manfred Hensel,Ulrich Dührsen,Jürgen Finke,Peter Dreger,Ulrich Jäger,Eva Lengfelder,Karin Hohloch,Ulrike Söling,Rudolf Schlag,Michael Kneba,Michael Hallek,Hartmut Döhner +18 more
TL;DR: Subcutaneous alemTuzumab appears as effective and safe as intravenous alemtuzumAB in fludarabine-refractory CLL and overcomes the adverse prognostic impact of VH mutation status, TP53 mutation, and genomic aberrations.
Journal ArticleDOI
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Holger Schulz,Saskia K. Klein,Ute Rehwald,Marcel Reiser,Axel Hinke,Wolfgang-Ulrich Knauf,Walter-Erich Aulitzky,Manfred Hensel,Michael Herold,Dieter Huhn,Michael Hallek,Volker Diehl,Andreas Engert +12 more
TL;DR: The combination of rituximab and fludarabine is feasible and effective in patients with B-CLL and the overall response rate was 87% and the median duration of response was 75 weeks.